Investigation of the Relation Between FAS, FASLG Polymorphisms and Serum Fas, FasL Levels in Patients with Psoriasis

Open access

Abstract

Background: Psoriasis is a multifactorial and inflammatory chronic skin disease indicated with T-cell-mediated keratinocyte hyper-proliferation. Demographic, epidemiological (family, twin), serological, and genetic studies have clearly demonstrated that psoriasis is a polygenic and multifactorial disease.

Aim: The objectives of the study are; to determine the prevalence of the polymorphisms of FAS (Fas cell surface receptor gene) -671 A>G (rs:1800682) and FASLG (Fas ligand gene) -844 T>C (rs:763110), to investigate the serum levels of sFas and sFasL, and also to discover any relationship between gene polymorphisms and serum levels in psoriatic patients.

Material and Methods: 50 treated and 69 untreated patients, and 140 healthy controls were included in the study. Polymorphisms were determined using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. The serum levels were measured in randomly selected treated (39) and untreated (40) patients, also in 84 healthy controls using micro-ELISA technique.

Results: There was no statistical difference between polymorphisms in the patient and control groups. However, sFas and sFasL levels in both treated and untreated patients were higher than that of the controls.

Conclusion: The investigated FAS and FASLG polymorphisms were not found to be directly associated with the psoriasis. Elevated sFas and sFasL levels in psoriatic patients showed that these factors may possess a significant role in the pathogenesis of psoriasis.

1. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64 Suppl 2: ii18-ii23. DOI: 10.1136/ard.2004.033217

2. Erkek E. Psoriazis Etyopatogenezi. Turkiye Klinikleri J Dermatol-Special Topics. 2008;1(3):1-14.

3. Roman II, Orasan MS, Coneac A, Marina EM, Pop AD, Orasan RI. Genetic and Hormonal Determinations in a Pair of Identical Twins with Early Onset Psoriasis Vulgaris: Case Report and a Brief Review of the Literature. Rev Romana Med Lab. 2017; 25(3):287-94 DOI: 10.1515/rrlm-2017-0021

4. Oskay T, Erdem C. Apopitoz ve Dermatolojideki Önemi. Turkiye Klinikleri J Dermatol. 2000;10(3):213-21.

5. Ada S. Psoriazis Sistemik Bir Hastalık mıdır? Turkiye Klinikleri J Dermatol-Special Topics. 2008;1(3):45-8.

6. Oskay T, KundakçI N. Psoriasisde genetik bulgular. Turkiye Klinikleri J Dermatol. 2000;10(2):139-45.

7. Asgari R, Yari K, Mansouri K, Bakhtiari M. Association analysis of FAS -670 A/G and FASL -844 C/T polymorphisms with risk of generalized agressive periodontitis disease. Biomed Rep. 2018;8 (4): 391-395.

8. Ozdemirkiran FG, Nalbantoglu S, Gokgoz Z, Payzin BK, Vural F, Cagiran S, Berdeli A. FAS/FASL gene polymorphisms in Turkish patients with chronic myeloproliferative disorders. Arch Med Sci. 2017;13(2): 426-432. DOI: 10.5114/aoms.2015.53963

9. Gilhar A, Yaniv R, Assy B, Serafimovich S, Ull-mann Y, Kalish RS. Fas pulls the trigger on psoriasis. Am J Pathol. 2006;168(1):170-5. DOI: 10.2353/aj-path.2006.041354

10. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281(5381):1305-8. DOI: 10.1126/science.281.5381.1305

11. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81(6):935-46. DOI: 10.1016/0092-8674(95)90013-6

12. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol. 1997;34(8-9):577-82. DOI: 10.1016/S0161-5890(97)00081-3

13. Kanemitsu S, Ihara K, Saifddin A, Otsuka T, Takeuchi T, Nagayama J, et al. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol. 2002;29(6):1183-8.

14. Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol. 2003;170(1):132-8. DOI: 10.4049/jimmunol.170.1.132

15. Seishima M, Seishima M, Takemura M, Saito K, Kitajima Y. Increased serum soluble Fas, tumor necrosis factor alpha and interleukin 6 concentrations in generalized pustular psoriasis. Dermatology. 1998;196(3):371-2.

16. Mysliwiec H, Baran A, Mysliwiec P, Gorska M, Flisiak I. Upregulation of the sFas/sFasL system in psoriatic patients. Add Med Sci. 2015;60(1):64-8. DOI: 10.1016/j.advms.2014.10.005

17. Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 2003;63(15):4327-30.

18. Xia B, Yu YH, Guo QS, Li XY, Jiang L, Li J. Association of Fas-670 gene polymorphism with inflammatory bowel disease in Chinese patients. World J Gastroenterol. 2005;11(3):415-7. DOI: 10.3748/wjg.v11.i3.415

19. Sun T, Zhou Y, Li H, Han X, Shi Y, Wang L, et al. FASL–844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J Exp Med. 2005;202(7):967-74. DOI: 10.1084/jem.20050707

20. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215. DOI: 10.1093/nar/16.3.1215

21. Ozel EG, Duran GG, Celik MM, Duran N, Gunesacar R. Fas and Fas ligand gene polymophisims in Turkish patient with Familial Mediterranean Fever. Gene. 2017; 623:29-32. DOI: 10.1016/j.gene.2017.04.037

22. Ghoreschi K, Mrowietz U, Röcken M. A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses. J Mol Med. 2003;81(8):471-80. DOI: 10.1007/s00109-003-0460-9

23. Allombert-Blaise C, Tamiji S, Mortier L, Fauvel H, Tual M, Delaporte E, et al. Terminal differentiation of human epidermal keratinocytes involves mitochondria- and caspase-dependent cell death pathway. Cell Death Differ. 2003;10(7):850-2. DOI: 10.1038/sj.cdd.4401245

24. Curtin JF, Cotter TG. Live and let die: regulatory mechanisms in Fas-mediated apoptosis. Cell Signal. 2003;15(11):983-92. DOI: 10.1016/S0898-6568(03)00093-7

25. Alenzi FQ. The role of apoptotic proteins in patients with systemic lupus erythematosis. Egypt J Immunol. 2009;16(1):107-16.

26. Islam Z, Jahan I, Ahammad RU, Shahnaij M, Nahar S, Mohammad QD. FAS promoter polymorphisms and serum sFas level are associated with increased risk of nerve damage in Banladeshi patients with Guillain-Barre syndrome. Plos One. 2018;12;13(2): e0192703.

27. Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne C, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest. 1993;69(4):415-29.

28. Kim K-M, Lee K, Hong Y-S, Park H-Y. Fas-mediated apoptosis and expression of related genes in human malignant hematopoietic cells. Exp Mol Med. 2000;32(4):246. DOI: 10.1038/emm.2000.41

29. Asgari R, Mansouri K, Bakhtiari M, Bidmeshkipour A, Yari K, Zadeh FS, Raygani AV. Association of FAS -670 A/G and FASL -844 C/T polymorphisms with idiopathic azospermia in Wertern Iran. Eur J Obstet Gynecol Reprod Biol. 2017; 218: 55-59. DOI: 10.1016/j.ejogrb.2017.09.003

30. Park JY, Lee W-K, Jung D-K, Choi J-E, Park T-I, Lee E-B, et al. Polymorphisms in the FAS and FASL Genes and Survival of Early Stage Non–small Cell Lung Cancer. Clin Cancer Res. 2009;15(5):1794-800. DOI: 10.1158/1078-0432.CCR-08-1770

Revista Romana de Medicina de Laborator

Romanian Journal of Laboratory Medicine

Journal Information


IMPACT FACTOR 2017: 0.400
5-year IMPACT FACTOR: 0.320



CiteScore 2017: 0.31

SCImago Journal Rank (SJR) 2017: 0.144
Source Normalized Impact per Paper (SNIP) 2017: 0.195

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 82 82 19
PDF Downloads 48 48 8